Daniel F. Martin, MD, Chair, Cole Eye Institute, discusses key five-year findings from the Comparison of AMD Treatments Trials (CATT) study at ARVO 2016.
Long-acting drug delivery ocular implants are being studied at Cole Eye Institute as a viable option to replace frequent injections and office visits.
Using minimally invasive glaucoma surgery as an adjunct to cataract surgery safely restores vision and reduces intraocular pressure in patients with pre-existing mild-to-moderate stage glaucoma.
Cleveland Clinic eye surgeon Rishi Singh, MD, is leading a first-of-its-kind international event—Retina World Conference—to support global scientific and clinical exchange on innovations in retina health.
New Cleveland Clinic research shows that serial hepatic USG — paired with confirmatory CT/MRI scans when needed — has high sensitivity and specificity for detecting asymptomatic uveal melanoma metastases.
Cleveland Clinic researchers demonstrate cell-specific responses to extracellular viruses, which may be helpful in uncovering the mechanisms behind determining a cell’s fate.
Risk of blindness is a side effect of hydroxychloroquine, a common drug for RA and lupus, but rates of adequate screening for toxicity could be improved.
Bennie Jeng, MD, says his residency training at Cleveland Clinic’s Cole Eye Institute provided exceptional clinical training with a slant toward creating academicians.
Cleveland Clinic successfully implanted the Argus II Retinal Prosthesis System in its first patient. Hear first-hand from our physician and her patient (VIDEO), who was completely blind from retinitis pigmentosa and has regained some vision.
Residency is a three-year journey that sets the trajectory of a career in ophthalmology. For many of us, our choice of where to complete our residency was a life-defining moment.